{
    "root": "a5ae7e2d-1580-406a-aedf-55680c8e4874",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "buprenorphine hydrochloride and naloxone hydrochloride dihydrate",
    "value": "20250131",
    "ingredients": [
        {
            "name": "BUPRENORPHINE HYDROCHLORIDE",
            "code": "56W8MW3EN1"
        },
        {
            "name": "NALOXONE HYDROCHLORIDE DIHYDRATE",
            "code": "5Q187997EE"
        },
        {
            "name": "ANHYDROUS CITRIC ACID",
            "code": "XF417D3PSL"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "TRISODIUM CITRATE DIHYDRATE",
            "code": "B22547B95K"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        }
    ],
    "indications": "buprenorphine naloxone sublingual tablets indicated maintenance treatment opioid dependence . buprenorphine naloxone sublingual tablets used part complete treatment plan include counseling psychosocial support .",
    "contraindications": "\u2022 administer buprenorphine naloxone sublingual tablets sublingually single daily dose . ( 2.1 ) \u2022 strongly consider prescribing naloxone time buprenorphine naloxone sublingual tablets initiated renewed patients treated opioid disorder potential relapse , putting risk opioid overdose ( 2.2 ) \u2022 avoid precipitating withdrawal , induction buprenorphine sublingual tablets undertaken objective clear signs withdrawal evident . induction , doses buprenorphine naloxone sublingual tablets progressively adjusted level holds patient treatment suppresses opioid withdrawal signs symptoms . ( 2.3 ) \u2022 recommended target buprenorphine naloxone sublingual tablets maintenance 16 mg/4 mg. ( 2.3 ) \u2022 administer buprenorphine naloxone sublingual tablets directed full prescribing information . ( 2.3 , 2.4 ) \u2022 discontinuing treatment , gradually taper avoid signs symptoms withdrawal . ( 2.7 )",
    "warningsAndPrecautions": "buprenorphine naloxone sublingual tablets , usp 2 mg/0.5 mg supplied speckled-peach peach , flat faced beveled edge tablets product identification \u201c 54 \u201d [ ] \u201c 122 \u201d one side plain . ndc 0054-0188-13 : bottle 30 tablets 8 mg/2 mg supplied speckled-peach peach , flat faced beveled edge tablets product identification \u201c 54 \u201d [ ] \u201c 375 \u201d one side plain . ndc 0054-0189-13 : bottle 30 tablets storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] dispense tight , light-resistant container defined usp . store buprenorphine naloxone sublingual tablets securely dispose properly [ patient counseling information ( 17 ) ] .",
    "adverseReactions": "buprenorphine naloxone sublingual tablets contraindicated patients history hypersensitivity buprenorphine naloxone serious , including anaphylactic shock , reported [ ( 5.9 ) ] .",
    "indications_original": "Buprenorphine and Naloxone Sublingual Tablets are indicated for the maintenance treatment of opioid dependence. Buprenorphine and Naloxone Sublingual Tablets should be used as part of a complete treatment plan to include counseling and psychosocial support.",
    "contraindications_original": "\u2022 Administer Buprenorphine and Naloxone Sublingual Tablets sublingually as a single daily dose. ( 2.1 ) \u2022 Strongly consider prescribing naloxone at the time Buprenorphine and Naloxone Sublingual Tablets are initiated or renewed because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose ( 2.2 ) \u2022 To avoid precipitating withdrawal, induction with Buprenorphine Sublingual Tablets should be undertaken when objective and clear signs of withdrawal are evident.  After induction, doses of Buprenorphine and Naloxone Sublingual Tablets should be progressively adjusted to a level that holds the patient in treatment and suppresses opioid withdrawal signs and symptoms. ( 2.3 ) \u2022 The recommended target dosage of Buprenorphine and Naloxone Sublingual Tablets for maintenance is 16 mg/4 mg. ( 2.3 ) \u2022 Administer Buprenorphine and Naloxone Sublingual Tablets as directed in the Full Prescribing Information. ( 2.3 , 2.4 ) \u2022 When discontinuing treatment, gradually taper to avoid signs and symptoms of withdrawal. ( 2.7 )",
    "warningsAndPrecautions_original": "Buprenorphine and Naloxone Sublingual Tablets, USP\n                  \n                  \n                     2 mg/0.5 mg are supplied as speckled-peach to peach, flat faced beveled edge tablets with product identification \u201c54\u201d [above] \u201c122\u201d on one side and plain on the other. \n                  \n                  NDC 0054-0188-13: Bottle of 30 Tablets\n                  \n                     8 mg/2 mg are supplied as speckled-peach to peach, flat faced beveled edge tablets with product identification \u201c54\u201d [above] \u201c375\u201d on one side and plain on the other.\n                  \n                  NDC 0054-0189-13: Bottle of 30 Tablets\n                  \n                     Storage\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.]\n                  Dispense in a tight, light-resistant container as defined in USP.\n                  Store Buprenorphine and Naloxone Sublingual Tablets securely and dispose of properly [see Patient Counseling\n                     Information (17)].",
    "adverseReactions_original": "Buprenorphine and Naloxone Sublingual Tablets are contraindicated in patients with a history of hypersensitivity to buprenorphine or naloxone as serious adverse reactions, including anaphylactic shock, have been reported [see Warnings and Precautions (5.9)]."
}